VACSERA

About Us

A Century of Service to Public Health

Vision

To achieve national self-sufficiency in serums and vaccines by expanding local production both quantitatively and qualitatively, adhering to international quality standards to obtain WHO accreditation, and keeping pace with global technological advancements.

Mission

Securing the country's needs for human and veterinary serums and vaccines, biotechnological medicines, blood and its derivatives, reagents and medical supplies.

Leadership

Dr. Sherif El-Fil

Prof. Dr. Sherif El-Fil

CEO, Holding Company for Biological Products and Vaccines

VACSERA's investments embody the localization of vaccine manufacturing in Egypt, advancements in R&D, infrastructure, and workforce development — a sustainable, forward-looking vision ensuring Egypt's current and future needs and supporting access to high-quality vaccines across the Middle East and Africa.

Our History

  1. ●
    1881

    Establishment of a small laboratory under the Health Department

  2. ●
    1893

    First production of smallpox vaccine in Egypt

  3. ●
    1907

    First production of rabies vaccine

  4. ●
    1939

    Production of smallpox, typhoid, and tetanus vaccines in Agouza

  5. ●
    1948

    First central blood bank in Egypt

  6. ●
    1972

    Egyptian General Authority for Biological Products & Vaccines established

  7. ●
    2002

    Transformed into a Holding Company (Presidential Decree 187/2002)

  8. ●
    2021

    Principal site for Egypt's first Phase III COVID-19 vaccine mega-trial

Our Role in Egypt's Public Health Ecosystem

VACSERA plays a pivotal role in supporting national immunization programs, pandemic response, animal health, and national blood transfusion services. Over the past 100+ years, it has overcome three pandemics: smallpox, cholera, and COVID-19.